TRUP

Business Context and Reporting Period

Company: Trupanion, Inc. (TRUP)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Trupanion provides medical insurance for cats and dogs in the U.S., Canada, and parts of Europe. The company operates two segments: a high-margin "Subscription Business" (direct-to-consumer) and a lower-margin "Other Business" (B2B underwriting, primarily for Pets Best).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 11% QoQ and 12% YTD compared to the prior year. Subscription business revenue grew 14% (Q2) and 15% (YTD), driven by a 9-10% increase in monthly average revenue per pet and higher enrollment.
• Profitability: Operating income improved significantly, rising 175% in Q2 and 1,226% YTD. This was driven by improved subscription margins and lower interest expense.
• Net Income Volatility: While YTD net income increased 48% to $11.7 million, Q2 net income decreased 27% to $6.8 million. The Q2 decline was primarily due to the absence of a $7.8 million one-time gain from a nonmonetary exchange of preferred stock for intellectual property that occurred in Q2 2025.
• Cost of Revenue: Veterinary invoice expense increased 9-13% across segments, reflecting higher veterinary inflation and increased pet months. However, the subscription business cost of revenue as a percentage of revenue improved (decreased) from 81% to 80% YTD.
• Debt Restructuring: The company repaid its prior credit facility in November 2025 and entered a new $120 million facility with PNC Bank. Interest expense decreased 50% in Q2 and 46% YTD due to lower outstanding balances and favorable terms.

Guidance, Outlook, and Risks

• Share Repurchase Program: In June 2026, the Board approved a new $100 million share repurchase program with no expiration date. No shares were repurchased in the first half of 2026.
• Pets Best Run-off: The company is winding down its relationship with Pets Best (the primary driver of the "Other Business" segment), with an expected end date in Q3 2028. This will reduce revenue diversification and increase reliance on the subscription segment.
• Acquisition Costs: Average Pet Acquisition Cost (PAC) increased to $307 YTD (up 13% from prior year) as the company deployed more capital to acquire new pets in a disciplined manner.
• Regulatory Capital: Significant liquidity is held within insurance subsidiaries ($344.1 million) to meet risk-based capital requirements, limiting immediate availability for general corporate use without regulatory approval.
• Forward-Looking Statements: Management notes that results are subject to veterinary inflation, pricing adjustment timing, and competitive pressures. No specific financial guidance for the full year 2026 was provided in this filing.

Investor Verification Checklist

• One-Time Gains: Verify the impact of the $7.8 million gain in 2025 on year-over-year net income comparisons; exclude this to assess core operational performance.
• Subscription Margins: Monitor the "Subscription cost of paying veterinary invoices" as a percentage of revenue (70.5% YTD 2026 vs 71.4% YTD 2025) to confirm margin expansion trends.
• Pets Best Transition: Track the decline in "Other Business" revenue and the associated run-off timeline to assess the impact on total revenue growth.
• Debt Covenants: Review the amended PNC Facility covenants (amended Q3 2026) to ensure compliance, particularly regarding the new share repurchase capacity.
• Reserve Adequacy: Review the "Reserve for Veterinary Invoices" development; the company reported $2.4 million in unfavorable development for the subscription segment YTD 2026.